MADRID, January 3, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma. (Logo: http://pho...
from PR Newswire: //www.prnewswire.co.uk/news-releases/pharmamar-has-requested-the-process-of-re-examination-for-aplidin-from-the-ema-667838773.html
No comments:
Post a Comment